| PRIMARY INFORMATION |
|---|
| ID | 1225 |
| PMID | 12695068 |
| Year | 2003 |
| Sequence | (Chain A: GIVEQCCTSICSLYQLENYCN)
(Chain B: FVNQHLCGSHLVEALYLVCGERGFFYTPKT) |
| Name | Insulin in poloxamer gel 408 |
| Length | 51 |
| N-Terminal Modification | Free |
| C-Terminal Modification | Free |
| Linear/ Cyclic | Cyclic (Chain A: C6-C11)(Chain A:C7-Chain B:C7) (Chain A:C20-Chain B:C19) |
| Chirality | L |
| Chemical Modification | None |
| Origin of Peptide | Polypeptide |
| Nature of Peptide/Cargo | It is used in the treatment diabetes mellitus and has immense therapeutic and commercial importance |
| Mechanism | Not mentioned |
| Cargo Sequence/Structure | None |
Name of cargo
| Not applicable |
| Assay | Franz diffusion cells, Radioimuunoassay |
| Enhancer | Linoleic acid |
| Properties of enhancer | Not mentioned |
| Concentration | 500 µl of gel formulation with 500 µl of linoleic acid (5% v / v) |
| Incubation time | 2 h |
| Tissue permeability (value with units) | Skin permeation parameters of insulin from poloxamer 407 gel using linoleic acid enhancer, Lag time (h)=0.65 (0.49) , Flux (µg/cm2 /h)=8.08 (0.20), Cumulative amount permeated (µg)=244.38 (30.21), Skin affinity=5.28 (2.37), (P<0.05), all values are n=3 |
| Tissue Sample | Female Sprague–Dawley rat skin |
| Ex vivo/In vivo/In vitro | ex vivo |
| SECONDARY INFORMATION |
|---|
| STRUCTURE | |
| SMILES | N.A. |
